Koers Enzymatica AB Nasdaq Stockholm
Aandelen
SE0003943620
Farmaceutische producten
Omzet 2024 * | 6 mln. 64,74 mln. 5,54 mln. | Omzet 2025 * | 11,54 mln. 125 mln. 10,67 mln. | Marktkapitalisatie | 52,08 mln. 562 mln. 48,15 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -43,19 mln. -3,7 mln. | Nettowinst (verlies) 2025 * | -1 mln. -10,8 mln. -924K | EV/omzet 2024 * | 9,1 x |
Nettoschuld 2024 * | 2,46 mln. 26,57 mln. 2,28 mln. | Nettoliquiditeiten 2025 * | 1,65 mln. 17,78 mln. 1,52 mln. | EV/omzet 2025 * | 4,37 x |
K/w-verhouding 2024 * |
-12,5
x | K/w-verhouding 2025 * |
-21,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 34,79% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01-01-07 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18-07-17 |
Director of Finance/CFO | 55 | 01-01-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19-12-16 |
Director/Board Member | 56 | 15-02-16 | |
Director/Board Member | 57 | 01-05-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,06% | 682 mld. | |
+30,35% | 586 mld. | |
-3,42% | 364 mld. | |
+18,02% | 327 mld. | |
+4,27% | 285 mld. | |
+15,53% | 240 mld. | |
+10,16% | 209 mld. | |
-8,14% | 203 mld. | |
+8,12% | 165 mld. |